The efficacy of adjuvant chemotherapy after total mesorectal excision without selective lateral lymph node dissection for locally advanced rectal cancer Authors: Shin Kameishi, Toshifumi Yamaguchi, Hiroki Hamamoto, Dai Okemoto, Nanako Matsuo, Takako Ikegami, Hiroyuki Kodama, Hiroki Yukami, Elham Fakhrejahani, Sang-Woong Lee, Hiroki Nishikawa Published: 2025 ABSTRACT The standard treatment for locally advanced rectal cancer (RC) in Japan is TME with or without lateral lymph node dissection (LLND) and subsequent adjuvant chemotherapy. The efficacy of chemotherapy after TME without LLND remains unclear, so we aimed to assess this efficacy. We retrospectively reviewed patients who underwent TME without LLND and received adjuvant chemotherapy between January 2010 and December 2020 at our institution. Relapse-free survival (RFS) and overall survival (OS) were assessed. Prognostic factors for RFS, including tumor location, chemotherapy regimen, and T and N factors were analyzed using univariate and multivariate analyses. Of 197 patients, 117 were eligible. The median age was 66 years (range 26–82). Tumor locations were Ra and Rb in 67 (57%) and 50 (43%) patients. Eighty (68%) and 37 (32%) patients received fluoropyrimidine monotherapy (single agent) and oxaliplatin-based therapy (doublet) as adjuvant chemotherapy. The 3-year RFS rate and 3-year OS rate were 73.6% (95% confidence interval [CI], 64.7–81.0%) and 95.5% (95% CI, 89.6–98.1%), respectively. In the univariate and multivariate analysis, none of these variables were identified as independent prognostic factors for RFS. TME without LLND followed by adjuvant chemotherapy in patients with RC demonstrated favorable 3-year RFS and OS rates. Introduction The standard treatment strategies for locally advanced rectal cancer (RC) differ between Western countries and Japan. In Western countries, the standard treatment is preoperative chemoradiotherapy followed by total mesorectal excision (TME)1. Conversely, in Japan, TME with lateral lymph node dissection (LLND) and postoperative adjuvant chemotherapy is one of the standard treatment options for patients with locally advanced RC without lateral lymph node enlargement2–4. Notably, the significance of LLND differs between Western countries and Japan. In Western countries, LLND is considered a highly complex procedure and should not be performed in cases where lateral lymph node metastasis is negative5. Furthermore, when lateral lymph node metastasis is present, it is generally regarded as a sign of systemic disease; notably, LLND is not performed in these regions because lateral lymph nodes are typically included in the radiation field. Importantly, a Japanese clinical trial (JCOG0212) showed that TME with LLND significantly reduced the local recurrence rate compared with TME alone in RC cases without evident lateral lymph node metastasis6. To achieve local control, LLND tends to be performed in Japan even when lateral lymph node metastasis is not evident. However, the JCOG0212 trial showed no significant differences in overall survival (OS) or relapse-free survival (RFS) between the two groups. Moreover, the incidence of grade 3–4 surgical complications was higher in the LLND group, with a tendency toward more frequent moderate or severe male sexual dysfunction7,8. Fluoropyrimidine-based agents, UFT, which is an oral chemotherapy drug that combines two components: tegafur, a prodrug of 5-fluorouracil, and uracil have demonstrated superiority in RFS compared to surgery alone9,10. However, this evidence includes many cases in which LLND or chemoradiotherapy was performed on the lymph nodes, and the efficacy of postoperative chemotherapy in preventing the recurrence of RC without LLND is unknown. Furthermore, the evidence remains limited compared with that for colon cancer. Given that the efficacy of anticancer drugs is not expected to differ significantly from that of colon cancer, adjuvant chemotherapy for RC is generally implemented based on the evidence of colon cancer in clinical practice. In Japan, the rectum is broadly divided into the sigmoid rectum (RS), the upper rectum (Ra), and the lower rectum (Rb) (Japanese Classification of Colorectal Carcinoma, 8th edition). Specifically, RS is defined from the level of the capitulum angle to the inferior border of the second sacral vertebra. Ra extends from the inferior border of the second sacral vertebra to the perineal reflection, and Rb spans from the perineal reflection to the superior border of the puborectalis muscle attachment. Importantly, there is no international consensus on whether RS should be categorized anatomically as part of the rectum or the colon. Furthermore, the effectiveness of adjuvant chemotherapy following TME without LLND for Ra or Rb RC remains unclear. Thus, we retrospectively evaluated this issue at our institution. Methods Patients and methods We retrospectively reviewed the medical records of patients with histologically confirmed pathological stage III (categorized according to the 8th edition of the UICC for) RC at Osaka Medical and Pharmaceutical University, Osaka, Japan, from January 2010 to December 2020. The inclusion criteria were as follows: primary tumor lesion located in the rectum with Ra or Rb. The tumor location was classified as Ra (upper rectum, from the rectosigmoid junction to the peritoneal reflection) or Rb (lower rectum, from the peritoneal reflection to the anal canal), according to the Japanese Classification of Colorectal Carcinoma 8th edition; Eastern Cooperative Oncology Group performance status of 0 to 2; histologically confirmed adenocarcinoma; TME without LLND; R0 resection as a microscopically margin-negative resection (Japanese Classification of Colorectal Carcinoma 8th edition); and no prior treatment such as neoadjuvant chemotherapy or radiotherapy before surgery. The LLND was omitted in patients without clinically suspected lateral pelvic lymph node enlargement, taking into account patient comorbidities and operative risk. For adjuvant chemotherapy, a fluoropyrimidine-based single regimen (single-agent) or fluoropyrimidine-platinum doublet regimen (doublet) was administered to selected patients at the physician’s discretion, and baseline characteristics were compared between the two groups. We evaluated RFS and OS in the analyzed cases. In the primary analysis, we analyzed the 3-year RFS and OS rates of all patients. For the subgroup analysis, we analyzed the 3-year OS and RFS based on lesion location, chemotherapy regimen, and stage. The prognostic factors of tumor location, adjuvant chemotherapy regimens, and T and N factors for RFS were explored using univariate and multivariate analyses. Statistical analysis Univariate and multivariate analyses were performed using Cox proportional hazards regression to identify the significant independent risk factors affecting RFS. For the multivariate Cox regression analysis, the following covariates were included: age, sex, tumor location (Ra/Rb), pathological stage (IIIA, IIIB, IIIC), and adjuvant regimen (single agent/doublet). Survival analysis was conducted using the Kaplan–Meier method, and differences were evaluated using the log-rank test. RFS was defined as the time from surgery to the date of recurrence or death of any cause. The OS was calculated from the time of surgery to death from any cause. Statistical significance was defined as a two-sided p value < 0.05. All statistical analyses were performed using JMP Pro version 17. Informed consent was waived for this study by Osaka Medical and Pharmaceutical University (OMPU) Hospital Institutional Review Board/Ethics Committee owing to its anonymity and retrospective nature. An information disclosure document approved by the Ethics Review Committee was published on the hospital’s website, guaranteeing study participants and others the opportunity to refuse research implementation or continuation. This study was approved by the Ethical Review Committee of OMPU Hospital (No.2023 − 154). Research permission was granted by the OMPU President. All methods were performed in accordance with relevant guidelines and regulations. The proportional hazards assumption for the Cox regression model was assessed using Schoenfeld residuals and visual inspection of log-minus-log survival plots, and no violation of the assumption was observed. Results Clinical and pathological characteristics of patients with pStage III RC Among the 197 registered patients, 117 were eligible. Figure 1 shows a CONSORT diagram of the study population. The clinicopathological characteristics of the 117 patients with pStage III RC are shown in Table 1. The median patient age was 66 years (range: 26–82 years). This study included 54 (46%) and 63 (54%) men and women, respectively. The tumor was located in the Ra and Rb in 67 (57%) and 50 (43%) patients, respectively. The depth of invasion was T1, T2, T3, and T4 in 16 (13%), 19 (16%), 77 (66%), and five (4%) patients, respectively. Lymph node metastasis was N1, N2, and N3 in 72 (61%), 43 (37%), and two (2%) patients, respectively. The pathological stage was IIIA, IIIB, and IIIC in 47 (40%), 61 (52%), and nine (8%) patients, respectively. Fig. 1Consort diagram. TME, tumor mesorectal excision; LLND, lateral lymph node dissection; Ra, upper rectum; Rb, lower rectum. Consort diagram. TME, tumor mesorectal excision; LLND, lateral lymph node dissection; Ra, upper rectum; Rb, lower rectum. Table 1Patient characteristics.N = 117Age, years Median (range)66 (26–82)Sex Male54 (46%)Tumor location Upper rectum (Ra)67 (57%) Lower rectum (Rb)50 (43%)TNM T 1/2/3/416 (13%)/ 19 (16%)/ 77 (66%)/ 5 (4%) N 1/2/372 (61%)/ 43 (37%)/ 2 (2%)Stage IIIA/IIIB/IIIC47 (40%)/ 61 (52%)/ 9 (8%)Adjuvant regimen Fluoropyrimidine alone80 (68%) Platinum doublet37 (32%) Table 1Patient characteristics.N = 117Age, years Median (range)66 (26–82)Sex Male54 (46%)Tumor location Upper rectum (Ra)67 (57%) Lower rectum (Rb)50 (43%)TNM T 1/2/3/416 (13%)/ 19 (16%)/ 77 (66%)/ 5 (4%) N 1/2/372 (61%)/ 43 (37%)/ 2 (2%)Stage IIIA/IIIB/IIIC47 (40%)/ 61 (52%)/ 9 (8%)Adjuvant regimen Fluoropyrimidine alone80 (68%) Platinum doublet37 (32%) Patient characteristics. Adjuvant chemotherapy Eighty patients (68%) received single agent. Baseline characteristics according to treatment regimen are summarized in Table 2. Patients in the doublet group were more likely to have advanced disease, including higher N factor (p = 0.006) and stage IIIC (p = 0.004), whereas age, sex, tumor location, histology, and T factor did not differ significantly between the groups. In contrast, 37 (32%) patients received doublet. Among patients who received a single agent, 45 (56%), 29 (36%), and six (8%) were treated with UFT, capecitabine, and S-1, respectively. Among those who received doublet, 27 (73%), seven (19%), and three (8%) patients were treated with CAPOX, FOLFOX, and SOX, respectively, as shown in Table 3. The median duration of chemotherapy for all patients was 5.52 months (range: 0.10–8.84). In the single agent group, the median duration of chemotherapy was 5.55 months (range: 0.10–8.84). Moreover, in the doublet group, the median duration of chemotherapy was 5.49 months (range: 0.66–8.77) despite the discontinuation of oxaliplatin in 32.4% of patients during treatment. Table 2Baseline characteristics according to adjuvant chemotherapy regimen.Single agent (n = 80)Doublet (n = 37)P value*Age, years Median (range)66 (32–82)66 (26–80)Sex Male37 (46%)17 (46%)0.976Tumor location Upper rectum (Ra)49 (61%)18 (49%)0.201 Lower rectum (Rb)31 (39%)19 (51%)Histrogy Intestinal72 (90%)33 (89%)0.894 Diffuse8 (10%)4 (11%)T factor T1-325 (31%)10 (27%)0.641 T455 (69%)27 (73%)N factor N156 (70%)16 (43%)0.006 N2-324 (30%)20 (54%)Stage IIIA36 (45%)11 (30%)0.004 IIIB41 (51%)20 (54%) IIIC3 (4%)6 (16%)*Statistical significance was set at p < 0.05. Table 2Baseline characteristics according to adjuvant chemotherapy regimen.Single agent (n = 80)Doublet (n = 37)P value*Age, years Median (range)66 (32–82)66 (26–80)Sex Male37 (46%)17 (46%)0.976Tumor location Upper rectum (Ra)49 (61%)18 (49%)0.201 Lower rectum (Rb)31 (39%)19 (51%)Histrogy Intestinal72 (90%)33 (89%)0.894 Diffuse8 (10%)4 (11%)T factor T1-325 (31%)10 (27%)0.641 T455 (69%)27 (73%)N factor N156 (70%)16 (43%)0.006 N2-324 (30%)20 (54%)Stage IIIA36 (45%)11 (30%)0.004 IIIB41 (51%)20 (54%) IIIC3 (4%)6 (16%)*Statistical significance was set at p < 0.05. Baseline characteristics according to adjuvant chemotherapy regimen. *Statistical significance was set at p < 0.05. Table 3Adjuvant regimen.FU alone (n = 80)Platinum doublet (n = 37)*UFT45 (56%)CapeOX27 (73%)Capecitabine29 (36%)FOLFOX7 (19%)S-16 (8%)SOX3 (8%)*An oral chemotherapy drug that combines two components: tegafur, a prodrug of 5-fluorouracil, and uracil. Table 3Adjuvant regimen.FU alone (n = 80)Platinum doublet (n = 37)*UFT45 (56%)CapeOX27 (73%)Capecitabine29 (36%)FOLFOX7 (19%)S-16 (8%)SOX3 (8%)*An oral chemotherapy drug that combines two components: tegafur, a prodrug of 5-fluorouracil, and uracil. Adjuvant regimen. *An oral chemotherapy drug that combines two components: tegafur, a prodrug of 5-fluorouracil, and uracil. Relapse-free survival and overall survival The 3-year RFS and 3-year OS rates in 117 patients were 73.6% (95% CI 64.7–81.0%) and 95.5% (95% CI 89.6–98.1%), respectively (Fig. 2a, b). In the univariate and multivariate analysis including age, sex, tumor location, pathological stage, and adjuvant regimen, none of these variables were identified as independent prognostic factors for RFS (Table 4). Fig. 2(a) Kaplan–Meier analysis of relapse-free survival for all patients. RFS, relapse-free survival; CI, confidence interval. (b) Kaplan–Meier analysis of overall survival for all patients. OS, overall survival; CI, confidence interval. (a) Kaplan–Meier analysis of relapse-free survival for all patients. RFS, relapse-free survival; CI, confidence interval. (b) Kaplan–Meier analysis of overall survival for all patients. OS, overall survival; CI, confidence interval. Table 4Univariate and multivariate analysis for recurrence-free survival.ParameterUnivariate analysisMultivariate analysisHazard ratio (95% CI)P value*Hazard ratio (95% CI)P value*Age <6511 ≥ 650.935 (0.470–1.859)0.8481.003 (0.493–2.044)0.992Sex Male11 Female0.953 (0.481–1.888)0.8900.920 (0.463–1.831)0.813Location Upper rectum (Ra)11 Lower rectum (Rb)1.368 (0.689–2.713)0.3711.597 (0.782–3.260)0.199Stage IIIA11 IIIB1.747 (0.811–3.765)0.1541.910 (0.876–4.166)0.104 IIIC2.011 (0.548–7.378)0.2922.569 (0.649–10.166)0.179Adj regimen Fluoropyrimidine alone11 Platinum doublet1.006 (0.476–2.125)0.9880.833 (0.376–1.844)0.652CI, confidence interval.*Statistical significance was set at p < 0.05. Table 4Univariate and multivariate analysis for recurrence-free survival.ParameterUnivariate analysisMultivariate analysisHazard ratio (95% CI)P value*Hazard ratio (95% CI)P value*Age <6511 ≥ 650.935 (0.470–1.859)0.8481.003 (0.493–2.044)0.992Sex Male11 Female0.953 (0.481–1.888)0.8900.920 (0.463–1.831)0.813Location Upper rectum (Ra)11 Lower rectum (Rb)1.368 (0.689–2.713)0.3711.597 (0.782–3.260)0.199Stage IIIA11 IIIB1.747 (0.811–3.765)0.1541.910 (0.876–4.166)0.104 IIIC2.011 (0.548–7.378)0.2922.569 (0.649–10.166)0.179Adj regimen Fluoropyrimidine alone11 Platinum doublet1.006 (0.476–2.125)0.9880.833 (0.376–1.844)0.652CI, confidence interval.*Statistical significance was set at p < 0.05. Univariate and multivariate analysis for recurrence-free survival. CI, confidence interval. *Statistical significance was set at p < 0.05. Regarding tumor location, the 3-year RFS of Ra and Rb was 77.0% (95% CI 65.2–85.7%) and 69.0% (HR:1.37, 95%CI 64.7–81.0%), respectively, showing no significant difference between the two groups (p = 0.368) (Fig. 3a). In terms of pathological stage, the 3-year RFS of patients with pStageIIIA, IIIB, and IIIC was 79.7% (95% CI 65.3–89.1%), 70.3% (HR:1.75, 95% CI 57.7–80.5%), and 64.8% (HR:2.01, 95% CI 30.8–88.4), respectively (Fig. 3b). Furthermore, concerning the chemotherapy regimen, the 3-year RFS of the single agent group was 74.4% (95% CI 63.6–82.9%), and that of the doublet group was 71.9% (HR: 1.01, 95%CI 55.1–84.2%, p = 0.988) (Fig. 3c). Finally, 35 (29.9%) patients had tumor recurrence: 13 with liver metastasis, 14 with lung metastasis, nine with lymph node metastasis, and one with peritoneal carcinomatosis (Table 5). Fig. 3(a) Kaplan–Meier analysis of relapse-free survival according to tumor location. RFS, relapse-free survival; Ra, upper rectum; Rb, lower rectum; HR, hazard ratio. (b) Kaplan–Meier analysis of relapse-free survival according to pathological stage. RFS, relapse-free survival; HR, hazard ratio. (c) Kaplan–Meier analysis of relapse-free survival according to each regimen. RFS, relapse-free survival; HR, hazard ratio. (a) Kaplan–Meier analysis of relapse-free survival according to tumor location. RFS, relapse-free survival; Ra, upper rectum; Rb, lower rectum; HR, hazard ratio. (b) Kaplan–Meier analysis of relapse-free survival according to pathological stage. RFS, relapse-free survival; HR, hazard ratio. (c) Kaplan–Meier analysis of relapse-free survival according to each regimen. RFS, relapse-free survival; HR, hazard ratio. Table 5Recurrence site (n = 35).Location n %Lung1440.0%Liver1337.1%Lymph node925.7%Peritoneal12.9% Table 5Recurrence site (n = 35).Location n %Lung1440.0%Liver1337.1%Lymph node925.7%Peritoneal12.9% Recurrence site (n = 35). Subgroup analysis of adjuvant chemotherapy regimens based on stage In pStageIIIA, the 3-year RFS of the single agent and doublet groups was 79.4% (95% CI 62.6–89.9%) and 80.8% (HR:0.81, 95%CI 47.2–95.2%, p = 0.796), respectively (Fig. 4a). In pStageIIIB, the 3-year RFS of the single agent and doublet groups was 70.6% (95% CI 55.1–82.6%) and 69.6% (HR:0.96, 95%CI 46.7–85.7%, p = 0.941), respectively. In pStageIIIC patients, the 3-year RFS of the single agent and doublet groups were 66.7% (95% CI 15.4–95.7%) and 62.5% (HR:1.06, 95%CI 21.9–90.9%), respectively, showing no significant difference between the two groups (p = 0.960) (Fig. 4a–c). Among the 117 patients, data on the total number of resected lymph nodes were available for all cases. Ten patients (8.5%) had fewer than 12 nodes examined, while 107 patients (91.5%) had 12 or more nodes, with a median of 20 nodes (range, 6–46). The 3-year RFS was 75.0% (95% CI: 65.7–82.4%) in the ≥ 12 group and 60.0% (95% CI: 29.7–84.2%) in the < 12 group, with no statistically significant difference (p = 0.523), although there was a trend favoring the ≥ 12 group. Importantly, all patients who received doublet chemotherapy had ≥ 12 lymph nodes examined. Fig. 4(a) Kaplan–Meier analysis of relapse-free survival for stage IIIA according to each regimen. RFS, relapse-free survival; HR, hazard ratio. (b) Kaplan–Meier analysis of relapse-free survival for stage IIIB according to each regimen. RFS, relapse-free survival; HR, hazard ratio. (c) Kaplan–Meier analysis of relapse-free survival for stage IIIC according to each regimen. RFS, relapse-free survival; HR, hazard ratio. (a) Kaplan–Meier analysis of relapse-free survival for stage IIIA according to each regimen. RFS, relapse-free survival; HR, hazard ratio. (b) Kaplan–Meier analysis of relapse-free survival for stage IIIB according to each regimen. RFS, relapse-free survival; HR, hazard ratio. (c) Kaplan–Meier analysis of relapse-free survival for stage IIIC according to each regimen. RFS, relapse-free survival; HR, hazard ratio. Discussion We investigated the efficacy of adjuvant chemotherapy in patients with pathological stage III RC who underwent TME without LLND. In the present study, the 3-year RFS and OS rates were 73.6% (95%CI: 64.7–81.0%) and 95.5% (95%CI: 89.6–98.1%), respectively, indicating favorable outcomes despite the omission of LLND. Subgroup analyses showed a trend toward worse 3-year RFS in patients with lower rectal tumors and higher stages; however, no statistically significant differences were observed. Similarly, no significant differences in 3-year RFS were noted between the chemotherapy regimens or stages. Our findings indicate favorable survival outcomes for patients without preoperative lateral pelvic lymph node enlargement who did not undergo LLND and received postoperative chemotherapy. Furthermore, adjuvant therapy with a single agent demonstrated efficacy comparable to that of doublet, indicating its potential suitability for patients unable to tolerate intensive regimens, such as older adults. To the best of our knowledge, this is the first study to evaluate single agents versus doublets in adjuvant chemotherapy for RC after TME without LLND. Some evidence supports the use of adjuvant chemotherapy for locally advanced RC. The ADORE trial showed that adjuvant FOLFOX improved disease-free survival (DFS) compared to fluorouracil plus leucovorin in patients with stage II or III RC located < 12 cm from the anal verge or below the perineal reflection after preoperative chemoradiotherapy and TME11. In the ADORE trial, the 3-year DFS was 71.6% (95% CI 64.6–78.6) in the FOLFOX group and 62.9% (55.4–70.4) in the fluorouracil plus leucovorin group (HR:0.657, 95% CI 0.434–0.994, p = 0.047). In contrast, in our study, the 3-year RFS rates in the postoperative single agent and doublet were 74.4% and 71.9%, respectively. Although a direct comparison is limited by differences in stages, locations, and definitions between DFS and RFS, our results appear to be comparable to those of the ADORE trial. In Japan, the NSAS-CC trial, which targeted colon cancer and RC without preoperative therapy, showed that postoperative adjuvant chemotherapy with UFT was significantly better in terms of RFS and OS than surgery alone for stage III RC10. In a pooled analysis of randomized controlled trials from Western countries for Dukes’ B and C patients, 5-FU plus l-LV showed an improvement in RFS and OS compared with surgery alone12. Furthermore, in the ACTS-RC trial, adjuvant chemotherapy with S-1 resulted in improved 5-year RFS in patients with curatively resected stage II/III RC located above the perineal reflection13. The ACTS-RC trial showed 5-year RFS rates of 61.7% and 66.4% in the UFT and S-1 groups, respectively, with 5-year OS rates of 80.2% and 82.0%, respectively. The outcomes of our study were favorable. Specifically, our findings demonstrated 5-year RFS rates of 69.9% (95% CI, 57.9–79.7%) in the single agent group and 71.9% (95% CI, 55.1–84.2%) in the doublet group, with 5-year OS rates of 85.9% (95% CI, 59.8–69.8%) and 91.7% (95% CI, 45.7–77.3%), respectively. Although we did not perform direct comparisons between specific monotherapy regimens because of differences in stages and locations, our results were at least equivalent to, if not exceeding, those of the ACTS-RC trial. Although the efficacy of oxaliplatin as adjuvant chemotherapy after upfront surgery for RC has not been tested, oxaliplatin-containing regimens are routinely used in clinical practice based on evidence from colon cancer. Adjuvant chemotherapy for stage III colon cancer and 6 months of oxaliplatin-based therapy (CAPOX or FOLFOX) were shown to reduce the relative risk of recurrence and death by approximately 20% compared with 6 months of 5-FU + l-LV therapy in the MOSAIC trial14. In stage III colon cancer, oxaliplatin has been shown to be effective as an add-on to standard treatments, including LV5FU2, bolus 5-FU (RPMI regimen), and capecitabine. Additionally, pooled analyses from the Adjuvant Colon Cancer Endpoints (ACCENT) group, which included data from several randomized trials such as NSABP C-06 and C-07, have evaluated the benefit of adding oxaliplatin to 5-FU/LV. These analyses demonstrated that the addition of oxaliplatin was associated with improvements in DFS and OS15. Based on these findings, CAPOX or FOLFOX regimens are considered treatment options for locally advanced RC after TME in clinical practice. In contrast, oxaliplatin-based therapy has been reported to result in significantly higher incidences of grade 3–4 treatment-related adverse events compared to 5-FU + l-LV therapy16. Specifically, peripheral neuropathy remains a significant concern not only during treatment but also in the long term. Currently, there are no strongly recommended effective prevention or treatment options for this condition. In terms of severe adverse events, our results suggest the feasibility of fluoropyrimidine monotherapy as a practical adjuvant treatment for RC. In recent years, total neoadjuvant therapy (TNT) for locally advanced RC has gained popularity in several countries. In the STELLAR trial, the 3-year OS rate in the TNT group was 86.5% (95% CI: 82.1–90.8%), compared to 75.1% (95% CI: 69.4–80.8%) in the chemoradiotherapy (CRT) group, showing no statistically significant difference (HR: 0.67, p = 0.33), yet a notable trend toward improved survival17. Furthermore, in the PRODIGE23 trial, the group receiving FOLFIRINOX prior to CRT achieved a significantly higher 3-year DFS of 76% (95% CI: 69–81%) compared to 69% (95% CI: 62–74%) in the CRT-alone group (HR: 0.69, p = 0.034)18. Long-term follow-up at 7 years also demonstrated an OS advantage in the TNT arm, with OS rates of 81.9% versus 76.1% (RMST benefit + 4.37 months; p = 0.033)19. Although TNT has shown promising results in randomized trials, these studies mainly enrolled younger patients (median age around 60 years), and the proportion of patients aged 70 years or older was very limited. Therefore, the feasibility and efficacy of TNT in older patients remain uncertain. Therefore, upfront surgery may be the most appropriate therapeutic approach for these patients. On the other hand, recent advances in neoadjuvant treatment strategies, including TNT, have increased the rates of pathological complete response, thereby raising the possibility of organ-preserving approaches such as local excision or a watch-and-wait strategy in selected patients. However, these approaches require careful patient selection and further validation of long-term oncological outcomes. Our study provides valuable evidence that can be applied to such cases. The clinical utility of circulating tumor DNA (ctDNA) in the management of colorectal cancer has garnered attention. Although we did not analyze ctDNA in our cohort, recent external studies have demonstrated its value. For example, in a study involving patients with stage II colon cancer, postoperative ctDNA testing was used to guide adjuvant chemotherapy. Those who were ctDNA-positive and received single agent or doublet achieved a 3-year RFS of 86.4%, whereas ctDNA-negative patients who did not receive adjuvant therapy had a 3-year RFS of 92.5% (HR: 1.83, 95% CI: 0.79–4.27)20. These results suggest that ctDNA assessment could serve as a key component in treatment strategies for RC. Our study provides valuable evidence that ctDNA is one of the determining factors for implementing adjuvant chemotherapy and may complement clinical decision-making in the future. This study had some limitations that warrant consideration. First, it was retrospective, and each physician individually selected the postoperative treatment. Second, cases involving LLND were excluded, precluding a direct comparison of the treatment efficacy with and without LLND. In our cohort, LLND was omitted according to the surgeon’s discretion in patients without clinically suspected lateral pelvic lymph node metastasis, and patient comorbidities or operative risk also influenced this decision. Therefore, the possibility of selection bias cannot be excluded, which should be considered when interpreting our results. Third, this study did not account for biomarkers, raising the possibility that genetic variation or bias may have influenced treatment outcomes. Fourth, the small sample size and single-institute design represent another limitation, reducing the generalizability of our findings. In particular, the subgroup analysis for stage IIIC disease was markedly underpowered because only nine patients were included. The 3-year RFS rates were 66.7% for single agent and 62.5% for doublet, but the 95% confidence intervals were extremely wide. A post-hoc power analysis demonstrated that even if a hazard ratio of 0.70 were assumed, the power was less than 10%. Therefore, the results of the stage IIIC subgroup analysis should be regarded as exploratory and interpreted with great caution. Although most baseline characteristics were comparable between the two groups, patients in the doublet group were more likely to present with advanced disease (higher N factor and stage IIIC). This indicates potential selection bias in the physician’s choice of regimen, and the results of the subgroup analyses should therefore be interpreted with caution. We also explored whether the total number of resected lymph nodes influenced survival outcomes or modified the efficacy of doublet chemotherapy. Using a conventional cut-off of 12 nodes, no statistically significant association with RFS was observed, although there was a trend toward better outcomes in patients with ≥ 12 nodes. Because only 10 patients had < 12 nodes, the analysis was underpowered, and these findings should be interpreted with caution. In addition, although we presented the distribution of recurrence sites, the limited number of events did not allow for meaningful statistical comparisons between chemotherapy regimens regarding site-specific recurrence patterns. Moreover, no variable remained statistically significant in the multivariate analysis, which likely reflects the limited number of recurrence events in our cohort and the reduced ability to detect independent prognostic factors. Fifth, detailed data on cT3 subclassification, TME quality, circumferential resection margin (CRM), and extramural venous invasion (EMVI) were not available, which may have affected the interpretation of prognostic outcomes. In conclusion, this study provides real-world evidence for adjuvant therapy in patients with stage III RC after TME without LLND in clinical practice. The addition of oxaliplatin to adjuvant chemotherapy did not demonstrate a significant benefit, and favorable treatment outcomes were achieved with fluoropyrimidine monotherapy. However, this was a retrospective study; therefore, further well-designed prospective studies are required to determine the most effective treatment protocols for this critical patient population.